Anavex Life Sciences Corp. AVXL 深 沪
已收盘 10-02 16:00:00 美东时间
1.82
-0.070
-3.70%
华盛通- 最 高1.88
- 今 开1.88
- 成交量 198.91万股
- 最 低 1.72
- 昨 收 1.89
- 总市值 1.69亿
- 52周最高 9.50
- 市盈率 静 --
- 换手率 2.15%
- 52周最低 1.72
- 委 比 30.83%
- 总股本 9269.68万
- 历史最高 31.50
- 量 比 1.19
- 振 幅 8.47%
- 历史最低 0.60
- 每 手 1
- 风险率 1.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
Anavex Life Sciences Corp. announced that all six of its director nominees were elected at its 2026 Annual Meeting of Stockholders. The newly elected Board includes Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz, and Dr. Claus van der Velden. Dr. Ma, the Independent Chair, expressed gratitude to stockholders for their support and reaffirmed the Board's commitment to advancing the Company's strategy an...
09-24 14:00
Glass Lewis says Anavex shareholders should vote for PVG Asset nominees
Proxy advisory firm Glass Lewis said that Anavex Life Sciences (AVXL) shareholders should vote for two of PVG Asset Management director nominees, Curtis Hogue and Jason Kolbert. Glass Lewis also advi...
09-18 01:31
Crypto.com gets approval for single-stock futures, CEO Kris Marszalek says
Crypto.com is now authorized to bring single-stock futures to the market, CEO Kris Marszalek said in a post on X. The company is working with the SEC and the CFTC to offer single-stock perps in the US...
09-17 12:00
Anavex Advances Rett Syndrome Phase 3 Trial Plans
Anavex Life Sciences ( ($AVXL) ) has shared an update. On September 9, 2026, An...
09-10 06:20
Anavex gains as PVG calls for board reshuffle
Anavex Life Sciences (AVXL) traded higher in the premarket on Friday after PVG Asset Management urged shareholders to vote in favor of its six board nominees at the neuro drug developer’s annual meeti...
09-04 21:07
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Anavex Life Sciences has regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its outstanding Form 10-Qs for Q2 and Q3 2026. The company's stock will continue trading on the Nasdaq Global Select Market under "AVXL." Anavex focuses on developing innovative CNS disease treatments and remains committed to advancing its clinical development strategy.
09-02 20:00
Anavex Life Sciences shares are trading higher after the company reported better-than-expected Q3 EPS results.
Anavex Life Sciences shares are trading higher after the company reported better-than-expected Q3 EPS results.
08-25 22:59
Anavex Life Sciences Q3 EPS $0.08 Beats $(0.08) Estimate
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.08) by 200 percent. This is a 150 percent increase over losses of $(0.16) per share from the same period last year.
08-25 20:03
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Anavex Life Sciences reported progress across its Alzheimer’s disease, Rett syndrome, and Fragile X syndrome programs. The company submitted clinical trial data for Alzheimer’s to the FDA, plans to discuss pediatric inclusion in Rett syndrome trials, and aims to submit an IND for Fragile X in September. Anavex also highlighted its financial position, with $118.3 million in cash, and upcoming industry events.
08-25 12:00
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
Anavex Life Sciences Corp. filed definitive proxy materials with the SEC ahead of its 2026 Annual Meeting, urging stockholders to vote "FOR" its six independent director nominees on the WHITE proxy card. The company highlighted its strategy to enhance long-term value, including advancing oral blarcamesine across three CNS indications (early Alzheimer's disease, Rett syndrome, and Fragile X syndrome) and refreshing the Board with two new independe...
08-11 12:00
